• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Is tigecycline drug of choice for cIAI and cSSTI?

作者信息

Hosgor-Limoncu M

出版信息

Int J Clin Pract. 2013 Jun;67(6):492-3. doi: 10.1111/ijcp.12169.

DOI:10.1111/ijcp.12169
PMID:23679901
Abstract
摘要

相似文献

1
Is tigecycline drug of choice for cIAI and cSSTI?替加环素是复杂性腹腔内感染（cIAI）和复杂性皮肤及软组织感染（cSSTI）的首选药物吗？
Int J Clin Pract. 2013 Jun;67(6):492-3. doi: 10.1111/ijcp.12169.
2
Clinical and microbiological efficacy of tigecycline for complicated skin-soft-tissue and intra-abdominal infections in a Turkish university hospital.土耳其某大学医院应用替加环素治疗复杂性皮肤软组织感染和腹腔内感染的临床和微生物学疗效。
Int J Clin Pract. 2013 Jun;67(6):505-11. doi: 10.1111/ijcp.12070.
3
Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials.替加环素治疗复杂性腹腔内感染和复杂性皮肤软组织感染临床试验的临床应答和死亡率。
Int J Antimicrob Agents. 2015 Sep;46(3):346-50. doi: 10.1016/j.ijantimicag.2015.05.012. Epub 2015 Jun 25.
4
Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies.欧洲多重耐药病原体的耐药机制和流行病学及替加环素在观察性研究中的疗效。
J Antimicrob Chemother. 2013 Jul;68 Suppl 2:ii45-55. doi: 10.1093/jac/dkt144.
5
Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies.替加环素治疗复杂性皮肤和软组织感染及腹腔内感染的安全性和耐受性：基于五项欧洲观察性研究的分析。
J Antimicrob Chemother. 2013 Jul;68 Suppl 2:ii37-44. doi: 10.1093/jac/dkt143.
6
Tigecycline: an antibiotic for the twenty-first century.替加环素：二十一世纪的抗生素。
J Antimicrob Chemother. 2013 Jul;68 Suppl 2:ii3-4. doi: 10.1093/jac/dkt139.
7
An essential requirement for the licensing of new antibiotics is the provision of data on efficacy and safety obtained from clinical trials in which patients are randomized to receive either the experimental drug or a comparator antibiotic regarded as a standard treatment option. Preface.
J Antimicrob Chemother. 2013 Jul;68 Suppl 2:ii1. doi: 10.1093/jac/dkt158.
8
Influence of age on the clinical efficacy of tigecycline in severely ill patients.年龄对重症患者替加环素临床疗效的影响。
J Glob Antimicrob Resist. 2019 Sep;18:199-206. doi: 10.1016/j.jgar.2019.03.018. Epub 2019 Apr 3.
9
Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities.德国多中心研究中 1025 例重症复杂感染患者的治疗：替加环素不同治疗方式的安全性特征和疗效。
Chemotherapy. 2012;58(4):282-94. doi: 10.1159/000342451. Epub 2012 Oct 4.
10
Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies.来自五个欧洲观察性研究的替加环素治疗真实临床实践中复杂性皮肤和软组织感染的疗效。
J Antimicrob Chemother. 2013 Jul;68 Suppl 2:ii15-24. doi: 10.1093/jac/dkt141.